---
title: "Giant Biogene Moves to Replace EY With KPMG as Auditor"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284777262.md"
description: "Giant Biogene Holding Co. Ltd. (HK:2367) is set to replace Ernst & Young with KPMG as its auditor after a seven-year tenure. This decision follows a corporate governance review and will be presented for shareholder approval at the upcoming annual general meeting. EY will complete the audit for the year ending December 31, 2025, with no expected disruptions to the audit schedule. The audit committee cited KPMG's technical competence and resources as key factors in their decision. The current analyst rating for the stock is a Hold with a price target of HK$35.00."
datetime: "2026-04-30T13:02:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284777262.md)
  - [en](https://longbridge.com/en/news/284777262.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284777262.md)
---

# Giant Biogene Moves to Replace EY With KPMG as Auditor

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Giant Biogene Holding Co. Ltd. ( (HK:2367) ) just unveiled an update.

Giant Biogene Holding Co. Ltd. has launched a planned change of auditors as part of its corporate governance review, deciding not to reappoint Ernst & Young after seven consecutive years of auditing its consolidated financial statements. EY will complete the audit for the year ended 31 December 2025 and retire at the conclusion of the upcoming annual general meeting, with the company stressing that the move will not affect the 2025 audit.

The board, following the audit committee’s recommendation, will seek shareholder approval at the AGM to appoint KPMG as the new auditor from the end of that meeting until the next annual general meeting. The audit committee cited KPMG’s scale, technical competence, independence, resources, and alignment with regulatory guidance as key reasons for its selection, and both EY and the board confirmed there are no disagreements or issues requiring shareholder attention, indicating a smooth transition with no expected disruption to the 2026 audit timetable.

The most recent analyst rating on (HK:2367) stock is a Hold with a HK$35.00 price target. To see the full list of analyst forecasts on Giant Biogene Holding Co. Ltd. stock, see the HK:2367 Stock Forecast page.

**More about Giant Biogene Holding Co. Ltd.**

Giant Biogene Holding Co. Ltd. is a Hong Kong-listed company engaged in the biopharmaceutical sector, operating through a group structure with various subsidiaries. The group focuses on producing and developing specialized biological products, positioning itself within regulated capital markets that emphasize strong corporate governance standards.

**Average Trading Volume:** 5,421,433

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$31.22B

### Related Stocks

- [02367.HK](https://longbridge.com/en/quote/02367.HK.md)

## Related News & Research

- [Giant Biogene Sets 2026 AGM to Refresh Board Mandates and Appoint New Auditor](https://longbridge.com/en/news/285394236.md)
- [Morgan Stanley Sticks to Its Buy Rating for Giant Biogene Holding Co. Ltd. (2367)](https://longbridge.com/en/news/270232349.md)
- [Tencent Music completes $2.6 billion acquisition of podcast platform Ximalaya](https://longbridge.com/en/news/286841981.md)
- [PTA-DD: Warimpex Finanz- und Beteiligungs AG: Managers' transactions announcement according to article 19 MAR](https://longbridge.com/en/news/286901864.md)
- [US energy secretary says China will be bigger buyer of US crude oil](https://longbridge.com/en/news/286567672.md)